Immunocytokines Market

Immunocytokines Market Overview

The global immunocytokines  market, valued at USD 847 million in 2025, is projected to reach USD 1,514 million in 2026 and USD 5,374 million by 2030, with a 37.3% CAGR during the forecast period 2026 to 2030.

To learn more about this report, request a free sample copy

Cancer is one of the leading causes of death worldwide, accounting for an estimated 0.6 million deaths in 2020, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70%, worldwide, over the next 20 years. It is a well-known fact that the conventional treatment options, such as chemotherapy, radiation therapy, and surgery, demonstrate limited efficacy in late-stage cancers. Moreover, the non-specific and highly toxic nature of traditional chemotherapy and radiation therapy, have been demonstrated to have detrimental effects on patients’ quality of life. Amongst the emerging class of targeted anti-cancer therapies, immunotherapy has emerged as a versatile option, having demonstrated the capability to selectively target and eliminate tumor cells. As a result, such products have favorable side effects profiles.

For instance, immune checkpoint inhibitors (such as atezolizumab, nivolumab, and pembrolizumab) have been demonstrated to offer long term clinical benefits to patients suffering from metastatic tumors. Similarly, other immunotherapies, such as dendritic cell therapy, T cell receptor transduced T cells, and chimeric antigen receptor (CAR)-modified T cells have shown promising results in eradicating primary and metastasized cancer cells. However, these therapies have been associated with severe and often life-threatening side effects, such as cytokine storm. Moreover, for T-cell therapy, mispairing of endogenous and transfected TCR α and β chains have been demonstrated to have detrimental biological effects. 

Traditionally, cytokines have been investigated as a therapeutic modality across multiple clinical trials, particularly as anti-cancer agents. However, the systemic administration of such potent, biologically-active molecules has been shown to be associated with a wide range of dose-dependent side effects and unfavorable pharmacokinetic properties, which, in a way, hinders dose escalation to therapeutically beneficial levels. To overcome the treatment-limiting toxicities of cytokines, researchers are now focusing on immunocytokines. Immunocytokines are fusion proteins, featuring the target specificity of antibodies and the immunological response mediating capabilities of specific cytokines. These engineered pharmacologically-active molecules have, so far, demonstrated better efficacy and reduced toxicity compared to conventional cytokine-based therapies.

As a result, immunocytokines are now being investigated for the treatment of a wide array of target indications, including cancers, autoimmune disorders, and certain chronic inflammatory diseases. It is also worth highlighting that this upcoming class of molecules has been demonstrated to work in synergy with certain other established therapeutics, including small molecule drugs (doxorubicin and cytarabine), intact antibodies (atezolizumab, durvalumab, ipilimumab, and nivolumab), radiation therapy, and other immunocytokines. Driven by encouraging virtual clinical trials result, this niche, but emerging domain, is poised to witness healthy market growth during the forecast period, with pioneers in the field likely to benefit from the first-to-market advantage.

Key Companies in Immunocytokines Market 

Examples of key companies engaged in immunocytokines market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Genopharm, ImmunGene, Kanaph Therapeutics, Merck KGaA and Philogen. This market report includes an easily searchable excel database of all the companies providing immunocytokines, worldwide.

Recent Developments in Immunocytokines Market:

Several recent developments have taken place in the field of immunocytokines market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In April 2026, PDS Biotechnology announced publication of Stage 1 Phase 2 data for its IL-12 tumor-targeted immunocytokine PDS01ADC in colorectal liver metastases. Results showed a 78% objective response rate and over 80% two-year survival, significantly outperforming control cohorts.
• In February 2026, A Phase Ib multicenter study evaluated cergutuzumab amunaleukin, an IL-2–based immunocytokine, combined with atezolizumab in advanced CEA-positive solid tumors. The trial assessed safety, pharmacokinetics, and dose escalation, establishing recommended dosing levels and demonstrating manageable safety with signs of anti-tumor activity in metastatic cancer patients.
• In January 2026, PDS Biotechnology reported preliminary Phase 2 results of its IL-12 immunocytokine PDS01ADC in metastatic castration-resistant prostate cancer. Presented at an AACR conference, the NCI-led study showed a median progression-free survival of 9.6 months in third-line patients, demonstrating potential clinical benefit in a difficult-to-treat population.

Scope of the Report

The “Immunocytokines Market, till 2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the immunocytokines market. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in immunocytokines market, over the next decade. Amongst other elements, the market research report includes:

• A detailed review of the current market landscape of immunocytokines, providing information on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of lead candidates, type of therapy (monotherapy and combination therapy), type of cytokine used (IL, IFN, TGF-β, TNF, and others), type of antibody used (anti-CD20, anti-CEA, anti-CTLA-4, anti-DNA, anti-EDA, anti-EDB, anti-FAP, anti-GC2, anti-Her2, anti-KS, anti-PD-L1, anti-PD-1, anti-TA-MUC1, and anti-Tenascin-C), target disease indications (blood cancer, brain cancer, breast cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, lung cancer, prostate cancer, renal cancer, rheumatoid arthritis, skin cancer, undisclosed solid tumors, and others), and route of administration (intravenous, intratumoral, subcutaneous, and others). In addition, the report presents the details of the companies developing these immunocytokines, including information on year of establishment, company size, and location of headquarters.
• Tabulated profiles of prominent immunocytokine developers. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.
• An analysis of recent developments in the field of immunocytokines market. It includes partnerships inked by various stakeholders in immunocytokines market, during the period between January 2016 and October 2020, covering clinical trial agreements, licensing agreements, mergers and acquisitions, research agreements, research and development agreements, and others. In addition, the report features an analysis of the investments made, including debt funding, equity, venture capital financing, capital raised from IPOs and subsequent offerings, at various stages of development, in companies that are focused on developing immunocytokines.
• An in-depth analysis of completed, ongoing, and planned clinical studies of various immunocytokines, based on various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication, and key geographical regions.
• A list of key opinion leaders (KOLs) within immunocytokines market, and detailed 2×2 matrices to assess the relative experience of key individuals who were shortlisted based on their contribution (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).

The key objective of immunocytokines market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for immunocytokines market during the forecast period. Based on various parameters, such as disease prevalence, anticipated adoption of immunocytokines, and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the forecast period till 2030.

The market report also features the likely distribution of the current and forecasted opportunity across [A] target disease indications (cervical cancer, cholangiocarcinoma, esophageal cancer, gallbladder cancer, head and neck cancer, melanoma, non-small cell lung cancer, rheumatoid arthritis, and soft tissue sarcoma), [B] routes of administration (intravenous, intratumoral, and subcutaneous), and [C] key geographical regions (US, Canada, Germany, UK, France, Italy, Spain, China, Japan, South Korea, Australia, Brazil, Argentina, Israel, and Turkey). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:

• Stephen Gillies, President and CEO, Provenance Biopharmaceuticals
• Patrik Kehler, Senior Director Scientific and Business Development, Glycotope

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are immunocytokines?

Answer: Immunocytokines are fusion proteins, featuring the target specificity of antibodies and the immunological response mediating capabilities of specific cytokines.

Question 2: How big is the immunocytokines market?

Answer: The immunocytokines market size is estimated to be worth $1,514 million in 2026.

Question 3: What is the projected market growth of the immunocytokines market?

Answer: The immunocytokines market is expected to grow at compounded annual growth rate (CAGR) of 37.3% during the forecast period till 2030.

Question 4: Who are the leading companies in the immunocytokines market?

Answer: Examples of key companies engaged in immunocytokines market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Genopharm, ImmunGene, Kanaph Therapeutics, Merck KGaA and Philogen.

Question 5: What is the dosage frequency of immunocytokines?

Answer: Immunocytokines are typically administered in doses featuring 20-60 million IU, once a week.

Question 6: How many potential therapeutic molecules are currently under development by the companies engaged in immunocytokines market?

Answer: Close to 80 potentially therapeutic molecules are currently under development by the companies engaged in immunocytokines market.

Question 7: How many clinical trials have been completed / ongoing in the immunocytokines market?

Answer: Over 90 clinical trials have been completed / ongoing in the immunocytokines market.